The (+)- and (-)-gossypols potently inhibit both 3β-hydroxysteroid dehydrogenase and 17β-hydroxysteroid dehydrogenase 3 in human and rat testes

Journal of Steroid Biochemistry and Molecular Biology

Volumn 115, Issue 1-2, 2009, Pages 14-19

  Hu, Guo Xin ^a,b   Zhou, Hong Yu ^a   Li, Xing Wang ^a   Chen, Bing Bing ^a   Xiao, Ye Chen ^b,c   Lian, Qing Quan ^a   Liang, Guang ^a   Kim, Howard H ^b,d   Zheng, Zhi Qiang ^a   Hardy, Dianne O ^b   Ge, Ren Shan ^a,b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b POPULATION COUNCIL   (United States)

^c JILIN AGRICULTURAL UNIVERSITY   (China)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Competitive inhibition; Hydroxysteroid dehydrogenase; Steroids; Testosterone

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; GOSSYPOL DERIVATIVE; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENANTIOMER; ENZYME BINDING; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; MALE; MICROSOME; NONHUMAN; RAT; SPECIES COMPARISON; TESTIS;

17-HYDROXYSTEROID DEHYDROGENASES; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; GOSSYPOL; HUMANS; INHIBITORY CONCENTRATION 50; MALE; RATS; SPECIES SPECIFICITY; TESTIS;

RATTUS;

EID: 67349158665     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.02.004     Document Type: Article

References (20)

1. Shi Y., Chatterjee S.J., Brands F.H., Shi S.R., Pootrakul L., Taylor C.R., Datar R., and Cote R.J. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations. BJU Int. 97 1 (2006) 170-178
2. Loberg R.D., St John L.N., Day L.L., Neeley C.K., and Pienta K.J. Development of the VCaP androgen-independent model of prostate cancer. Urol. Oncol. 24 2 (2006) 161-168
3. Qian S.Z., and Wang Z.G. A potential antifertility agent for males. Ann. Rev. Pharmacol. Toxicol. 24 (1984) 329-360
4. Den Boer P.J., and Grootegoed J.A. Differential effects of (+)- and (-)-gossypol enantiomers on LDH-C4 activity of hamster spermatogenic epithelium in vitro. J. Reprod. Fertil. 83 2 (1988) 701-709
5. Matlin S.A., Zhou R., Bialy G., Blye R.P., Naqvi R.H., and Lindberg M.C. (-)-Gossypol: an active male antifertility agent. Contraception 31 2 (1985) 141-149
6. Oliver C.L., Bauer J.A., Wolter K.G., Ubell M.L., Narayan A., O'Connell K.M., Fisher S.G., Wang S., Wu X., Ji M., Carey T.E., and Bradford C.R. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin. Cancer Res. 10 22 (2004) 7757-7763
7. Mohammad R.M., Wang S., Aboukameel A., Chen B., Wu X., Chen J., and Al Katib A. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol. Cancer Ther. 4 1 (2005) 13-21
8. Jiang J., Sugimoto Y., Liu S., Chang H.L., Park K.Y., Kulp S.K., and Lin Y.C. The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor beta1 (TGFbeta1) signal transduction pathway. Anticancer Res. 24 1 (2004) 91-100
9. Wolter K.G., Wang S.J., Henson B.S., Wang S., Griffith K.A., Kumar B., Chen J., Carey T.E., Bradford C.R., and D'Silva N.J. (-)-Gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia 8 3 (2006) 163-172
10. Van Poznak C., Seidman A.D., Reidenberg M.M., Moasser M.M., Sklarin N., Van Zee K., Borgen P., Gollub M., Bacotti D., Yao T.J., Bloch R., Ligueros M., Sonenberg M., Norton L., and Hudis C. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res. Treat. 66 3 (2001) 239-248
11. Loberg R.D., McGregor N., Ying C., Sargent E., and Pienta K.J. In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. Neoplasia 9 12 (2007) 1030-1037
12. Ge R.S., Gao H.B., Nacharaju V.L., Gunsalus G.L., and Hardy M.P. Identification of a kinetically distinct activity of 11β-hydroxysteroid dehydrogenase in rat Leydig cells. Endocrinology 138 6 (1997) 2435-2442
13. Sriraman V., Niu E., Matias J.R., Donahoe P.K., Maclaughlin D.T., Hardy M.P., and Lee M.M. Mullerian inhibiting substance inhibits testosterone synthesis in adult rats. J. Androl. 22 (2001) 750-758
14. Brozic P., Lanisnik R.T., and Gobec S. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Curr. Med. Chem. 15 2 (2008) 137-150
15. Reidenberg M.M. Environmental inhibition of 11beta-hydroxysteroid dehydrogenase. Toxicology 144 1-3 (2000) 107-111
16. Coutinho E.M., Athayde C., Atta G., Gu Z.P., Chen Z.W., Sang G.W., Emuveyan E., Adekunle A.O., Mati J., Otubu J., Reidenberg M.M., and Segal S.J. Gossypol blood levels and inhibition of spermatogenesis in men taking gossypol as a contraceptive. A multicenter, international, dose-finding study. Contraception 61 1 (2000) 61-67
17. Koh E., Noda T., Kanaya J., and Namiki M. Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate 53 2 (2002) 154-159
18. Biancolella M., Valentini A., Minella D., Vecchione L., D'Amico F., Chillemi G., Gravina P., Bueno S., Prosperini G., Desideri A., Federici G., Bernardini S., and Novelli G. Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest. New Drugs 25 5 (2007) 491-497
19. Margiotti K., Kim E., Pearce C.L., Spera E., Novelli G., and Reichardt J.K. Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men. Prostate 53 1 (2002) 65-68
20. Huang Y.W., Wang L.S., Chang H.L., Ye W., Sugimoto Y., Dowd M.K., Wan P.J., and Lin Y.C. Effects of serum on (-)-gossypol-suppressed growth in human prostate cancer cells. Anticancer Res. 26 5A (2006) 3613-3620